[go: up one dir, main page]

TNSN99145A1 - Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Info

Publication number
TNSN99145A1
TNSN99145A1 TNTNSN99145A TNSN99145A TNSN99145A1 TN SN99145 A1 TNSN99145 A1 TN SN99145A1 TN TNSN99145 A TNTNSN99145 A TN TNSN99145A TN SN99145 A TNSN99145 A TN SN99145A TN SN99145 A1 TNSN99145 A1 TN SN99145A1
Authority
TN
Tunisia
Prior art keywords
aminophenyle
furanyle
sulfonyle
isobutyle
benzyle
Prior art date
Application number
TNTNSN99145A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TNSN99145A1 publication Critical patent/TNSN99145A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

-L'INVENTION PORTE SUR LE CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S,2R) -3-[[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE) AMINO]-1-BENZYLE-2- (PHOSPHONOOXY) PROPYLCARBAMATE, SUR LES PROCEDES POUR SA PREPARATION, ET SUR SON UTILISATION DANS LE TRAITEMENT DES MALADIES CAUSEES PAR LES RETROVIRUS.
TNTNSN99145A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate TNSN99145A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
TNSN99145A1 true TNSN99145A1 (fr) 2005-11-10

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99145A TNSN99145A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Country Status (47)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1098898B1 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
CZ300031B6 (cs) * 1999-10-06 2009-01-14 Tibotec Pharmaceuticals Ltd. Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl) (isobutyl)amino]-1-benzyl-2-hydroxypropyl}karbamát a farmaceutický prípravek s jeho obsahem
DE60017180T2 (de) 1999-10-08 2005-12-08 Affinium Pharmaceuticals, Inc., Toronto Fab i inhibitoren
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
CN101074242A (zh) * 2002-04-26 2007-11-21 吉里德科学公司 Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
SI1575951T1 (sl) * 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
DE602004016831D1 (de) 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
CA2523083C (fr) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005047898A2 (fr) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Procedes et compositions pour l'identification des composes therapeutiques
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
ES2297467T3 (es) * 2003-09-30 2008-05-01 Tibotec Pharmaceuticals Ltd. Sulfonamidas de inhibicion de vhc.
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
KR20060127906A (ko) 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
EP2848614A3 (fr) * 2004-06-04 2015-07-29 Debiopharm International SA Dérivés de acrylamide et leur utilisation comme agents antibiotiques
AP2412A (en) 2004-07-27 2012-06-01 Gilead Sciences Inc Phosphonate analogs of HIV inhibitor compounds.
EA018007B1 (ru) 2004-11-26 2013-04-30 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2687533B1 (fr) 2006-07-20 2017-07-19 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de FAB I
WO2008098374A1 (fr) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
MX2009009850A (es) 2007-03-12 2009-09-24 Nektar Therapeutics Conjugados de inhibidor de oligomero-proteasa.
EP2262538B1 (fr) * 2008-03-12 2014-12-10 Nektar Therapeutics Conjugués oligomères-acides aminés
EP2307435B1 (fr) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Sels de composés inhibiteurs du vih
KR101975726B1 (ko) 2009-04-03 2019-05-07 오세라 테라퓨틱스, 아이엔씨. Ｌ-오르니틴 페닐 아세테이트, 및 이의 제조방법
EP2432788A1 (fr) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Fosamprenavir calcique amorphe
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
EP2440249A2 (fr) 2009-06-12 2012-04-18 Nektar Therapeutics Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique
WO2011001383A1 (fr) * 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Forme cristalline de fosamprénavir calcium
EP2477996A1 (fr) * 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Procédé pour préparer du fosamprénavir calcium
WO2011085130A1 (fr) * 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
US20130211108A1 (en) * 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
EP2614055A2 (fr) 2010-09-10 2013-07-17 Lupin Limited Procédé de préparation de calcium de fosamprenavir sensiblement pur et de ses intermédiaires
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
WO2013105118A1 (fr) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Procédé pour la synthèse d' azido-époxyde synthétique et son utilisation en tant qu'intermédiaire de la synthèse d'amprénavir et de saquinavir
LT2861608T (lt) 2012-06-19 2019-07-10 Debiopharm International Sa (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-nafthidrin-3-il)akrilamido provaisto dariniai
EP3685841A1 (fr) 2014-11-24 2020-07-29 Ucl Business Ltd Traitement de maladies associées à l'activation de cellules hépatiques de kupffer utilisant des thérapies de réduction d'ammoniac
CA2995823A1 (fr) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Traitement et prevention de la perte musculaire au moyen de l-ornithine en combinaison avec au moins un parmi l'acetate de phenyle et le butyrate de phenyle
AU2017223037B2 (en) 2016-02-26 2022-04-14 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
WO2018208677A1 (fr) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Procédés de fabrication de l-ornithine phénylacétate
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
CN116327781A (zh) 2019-02-14 2023-06-27 德彪药业国际股份公司 阿法比星制剂及其制备方法
MX2021015513A (es) 2019-06-14 2022-04-20 Debiopharm Int Sa Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
BR9814484A (pt) * 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2000018384A2 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
WO2000025784A1 (fr) * 1998-11-04 2000-05-11 Pharmacia & Upjohn Company Methode destinee a ameliorer la pharmacocinetique du tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ATE377011T1 (de) * 1999-11-24 2007-11-15 Merck & Co Inc Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer

Also Published As

Publication number Publication date
GEP20033030B (en) 2003-07-25
AR019388A1 (es) 2002-02-13
EA003191B1 (ru) 2003-02-27
IL140824A0 (en) 2002-02-10
PL195736B1 (pl) 2007-10-31
HUP0103432A2 (hu) 2002-04-29
NZ509291A (en) 2003-05-30
GB9815567D0 (en) 1998-09-16
AU766056B2 (en) 2003-10-09
IL140824A (en) 2004-09-27
JO2114B1 (en) 2000-05-21
AP2001002039A0 (en) 2001-03-31
CA2337857A1 (fr) 2000-01-27
JP3437553B2 (ja) 2003-08-18
HK1034261A1 (en) 2001-10-19
PL345620A1 (en) 2002-01-02
TR200100111T2 (tr) 2002-02-21
HUP0103432A3 (en) 2003-01-28
CN1188422C (zh) 2005-02-09
CA2337857C (fr) 2011-01-25
NO329676B1 (no) 2010-11-29
EP1240903A3 (fr) 2003-02-12
YU3401A (sh) 2005-06-10
EP1098898B1 (fr) 2002-12-18
NO20010282L (no) 2001-03-07
EE200100038A (et) 2002-06-17
KR100694721B1 (ko) 2007-03-15
IS5808A (is) 2001-01-12
BR9912156A (pt) 2001-04-10
EP1098898A1 (fr) 2001-05-16
DE69904600T2 (de) 2003-11-13
EP1240903A2 (fr) 2002-09-18
DZ2845A1 (fr) 2003-12-01
US20030096795A1 (en) 2003-05-22
BRPI9912156B1 (pt) 2016-07-26
OA11706A (en) 2005-01-13
US6514953B1 (en) 2003-02-04
ES2189450T3 (es) 2003-07-01
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
ZA200100417B (en) 2002-02-27
PT1098898E (pt) 2003-04-30
GC0000105A (en) 2005-06-29
CZ2001219A3 (cs) 2001-07-11
DE69904600D1 (de) 2003-01-30
CO5090836A1 (es) 2001-10-30
CN1324363A (zh) 2001-11-28
TWI245770B (en) 2005-12-21
DK1098898T3 (da) 2003-04-07
ID28070A (id) 2001-05-03
BRPI9912156B8 (pt) 2021-05-25
CZ300447B6 (cs) 2009-05-20
SV1999000096A (es) 2000-07-06
JP2003521447A (ja) 2003-07-15
NO20010282D0 (no) 2001-01-17
GT199900111A (es) 2001-01-05
SK762001A3 (en) 2001-10-08
EA200100053A1 (ru) 2001-08-27
WO2000004033A1 (fr) 2000-01-27
PE20000869A1 (es) 2000-09-08
MY122323A (en) 2006-04-29
BG105253A (en) 2001-12-29
AU5037999A (en) 2000-02-07
MA26660A1 (fr) 2004-12-20
PA8477801A1 (es) 2000-05-24
HRP20010046A2 (en) 2002-02-28
SK285311B6 (sk) 2006-10-05
ATE229964T1 (de) 2003-01-15
HU229700B1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
TNSN99145A1 (fr) Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate
TR199802423T2 (xx) Konsantre antikor terkibi.
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
WO2003103575A3 (fr) Composes, compositions et procedes
MA28289A1 (fr) Immunoglobulines
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
TNSN95088A1 (fr) Benzoxazolyl - et benzothiazolyloxazolidinones
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
YU7797A (sh) Kombinovana terapija za osteoporozu
SE9704546D0 (sv) Novel compounds
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
AP9801269A0 (en) Prostaglandin agonists.
DE60018085D1 (de) Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
BR0012921A (pt) Compostos calcilìticos
ATE415960T1 (de) Toluolsulfonamid enthaltende antitumorale zusammensetzung und anwendungsverfahren dafür
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen